← Patent-cliff monitor small molecule FARXIGA DAPAGLIFLOZIN
Loss of exclusivity November 2030 latest FDA-listed patent expiry
Company ASTRAZENECA AB
Drug detail Brand name FARXIGA Active ingredient DAPAGLIFLOZIN Strength 5MG Dosage form TABLET Route ORAL Modality Small molecule FDA approval January 2014 Marketing status RX
Listed patents Patent Expires Type 8685934*PED November 2030 — 8721615*PED July 2030 — 7919598*PED June 2030 — 8685934 May 2030 use U-1522 8721615 January 2030 product 7919598 December 2029 substance 7851502*PED February 2029 — 8221786*PED September 2028 — 8361972*PED September 2028 — 8716251*PED September 2028 — 7851502 August 2028 product 8716251 March 2028 product 8361972 March 2028 use U-493 8221786 March 2028 product 8501698*PED December 2027 — 8501698 June 2027 product 8329648*PED February 2027 — 8906851*PED February 2027 — 8329648 August 2026 use U-2212 8906851 August 2026 use U-2139 6515117*PED April 2026 — 6515117 October 2025 substance, product
Regulatory exclusivity Code Expires PED December 2027 NPP June 2027 PED November 2026 M-298 May 2026
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.